<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcium chloride: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcium chloride: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Calcium chloride: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9186" href="/d/html/9186.html" rel="external">see "Calcium chloride: Drug information"</a> and <a class="drug drug_patient" data-topicid="11304" href="/d/html/11304.html" rel="external">see "Calcium chloride: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866171"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Calciject</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1002895"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Calcium Salt</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Parenteral</span></li></ul></div>
<div class="block don drugH1Div" id="F53462389"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> 1,000 mg of calcium chloride = 270 mg of <b>elemental</b> calcium = 14 mEq of <b>elemental </b>calcium.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Dosing may be presented as calcium chloride or as <b>elemental</b> calcium and expressed as mg/kg or mEq/kg; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="182e8bc1-478c-4f91-a7d4-d64f248c385d">Calcium channel blocker toxicity, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker toxicity, treatment:</b> Limited data available: Neonates: Dose expressed as <b>calcium chloride</b>: IV: Bolus dose: 10 to 20 mg/kg/dose infused over 10 to 15 minutes; if ineffective, may repeat bolus dose every 10 to 15 minutes or initiate continuous IV infusion: 20 to 50 mg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-19687715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-19687715'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58ed2141-df17-4fed-8dc6-347ffb8349ff">Cardiac arrest in the presence of hyperkalemia or hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac arrest in the presence of hyperkalemia or hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity (PALS recommendations):</b>
<b>Note:</b> Calcium chloride is the preferred salt in urgent situations; not recommended in the absence of hyperkalemia, hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity due to the lack of improved survival (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-26473000','lexi-content-ref-20956230','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-26473000','lexi-content-ref-20956230','lexi-content-ref-33081526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Dose expressed as <b>calcium chloride</b>: IV, Intraosseous: 20 mg/kg/dose; may consider repeat dose in 10 minutes if clinically necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82060cb4-89c1-480c-96b2-5e3fb54c7b3f">Hypocalcemia, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia, symptomatic:</b>
<b>Note</b>: Calcium gluconate may be the preferred salt due to lower extravasation risks which are greater during peripheral venous administration and due to potential for metabolic acidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1','lexi-content-ref-7836618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1','lexi-content-ref-7836618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV infusion: Dose expressed as <b>calcium chloride</b>: 10 to 20 mg/kg/dose, may repeat every 4 to 6 hours as needed based on clinical response and desired effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-2246705','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-2246705','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Dose expressed as <b>calcium chloride</b>: Usual range: 3 to 11 mg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15013473','lexi-content-ref-31320908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15013473','lexi-content-ref-31320908'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75ef6aa3-9fab-4edd-a577-0bec1ed4ec02">Low cardiac output</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Low cardiac output</b>
<b> (adjunct therapy):</b> Limited data available: Neonates: Dose expressed as <b>calcium chloride</b>: Continuous IV infusion: Initial: 5 to 10 mg/kg/<b>hour</b>. Dosing based on retrospective review of pediatric calcium chloride infusions (n=116 infusions [65 infusions in neonates]) for low cardiac output of surgical and nonsurgical etiologies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26687150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26687150'])">Ref</a></span>). Another retrospective study did not show benefit of calcium chloride infusion following cardiac surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34523025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34523025'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71988c4f-1929-4cb5-842d-f039c8b31808">Parenteral nutrition, maintenance calcium requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition (PN), maintenance calcium requirement: Note:</b> Calcium gluconate is the preferred salt formulation for the preparation of PN, as it is less reactive than calcium chloride (at equivalent amounts) and it allows for improved solubility with phosphate salts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15568296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Dose expressed as <b>elemental calcium</b>: IV: 2 to 4 <b>mEq</b>/kg/<b>day </b>as an additive to PN solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASPEN.1','lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASPEN.1','lexi-content-ref-15568296'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F144506"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> 1,000 mg of calcium chloride = 270 mg of <b>elemental</b> calcium = 14 mEq of <b>elemental </b>calcium.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Dosing may be presented as calcium chloride or as <b>elemental</b> calcium and expressed as mg or mEq; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88c42725-2221-4888-8861-df1666363877">Calcium channel blocker toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker toxicity: </b> Infants, Children, and Adolescents: Dose expressed as <b>calcium chloride</b>: IV: 10 to 20 mg/kg/dose infused over 5 to 10 minutes; if effective, may repeat bolus doses every 10 to 15 minutes or initiate continuous IV infusion at 20 to 50 mg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-26473000','lexi-content-ref-20956230','lexi-content-ref-19687715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-26473000','lexi-content-ref-20956230','lexi-content-ref-19687715'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58ed2141-df17-4fed-8dc6-347ffb8349ff">Cardiac arrest in the presence of hyperkalemia or hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac arrest in the presence of hyperkalemia or hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity (PALS recommendations): Note:</b> Calcium chloride is the preferred salt in urgent situations; not recommended in the absence of hyperkalemia, hypocalcemia, hypermagnesemia, or calcium channel blocker toxicity due to the lack of improved survival (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-26473000','lexi-content-ref-20956230','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-26473000','lexi-content-ref-20956230','lexi-content-ref-33081526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Dose expressed as <b>calcium chloride</b>: IV, Intraosseous: 20 mg/kg/dose, maximum dose: 2,000 mg/dose; may consider repeat dose in 10 minutes if clinically necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82060cb4-89c1-480c-96b2-5e3fb54c7b3f">Hypocalcemia, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia, symptomatic:</b>
<b>Note</b>: Calcium gluconate may be the preferred salt in non-cardiac arrest settings due to extravasation risks which are greater during peripheral venous administration and due to potential for metabolic acidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230','lexi-content-ref-Corkins.1','lexi-content-ref-7836618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230','lexi-content-ref-Corkins.1','lexi-content-ref-7836618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Dose expressed as <b>calcium chloride</b>: IV: 10 to 20 mg/kg/dose, maximum dose: 1,000 mg/dose; repeat as needed based on clinical response and desired effect; some experts suggest every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75ef6aa3-9fab-4edd-a577-0bec1ed4ec02">Low cardiac output</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Low cardiac output</b>
<b> (adjunct therapy):</b> Limited data available: Infants, Children, and Adolescents: Dose expressed as <b>calcium chloride</b>: Continuous IV infusion: 5 to 10 mg/kg/<b>hour</b>. Dosing based on retrospective report of pediatric calcium infusions (n=116 [51 infusions in ages 1 month to 17 years]) for low cardiac output of surgical and nonsurgical etiologies; study results did not show a statistically significant difference in improvement of cardiac output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26687150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26687150'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71988c4f-1929-4cb5-842d-f039c8b31808">Parenteral nutrition, maintenance calcium requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition (PN), maintenance calcium requirement: Note:</b> Calcium gluconate is the preferred salt formulation for the preparation of PN since it is less reactive than calcium chloride (at equivalent amounts) and allows for improved solubility with phosphate salts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15568296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤50 kg: Dose expressed as <b>elemental calcium</b>: IV: 0.5 to 4 <b>mEq</b>/kg/<b>day</b> as an additive to PN solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15568296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;50 kg and Adolescents: Dose expressed as <b>elemental calcium</b>: IV: 10 to 20 <b>mEq</b>/<b>day </b>as an additive to PN solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15568296'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51083785"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage recommendations in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51083786"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage recommendations in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F144499"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9186" href="/d/html/9186.html" rel="external">see "Calcium chloride: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> One gram of calcium chloride salt is equal to 270 mg of elemental calcium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosages are expressed in terms of the <span style="text-decoration: underline">calcium chloride salt</span> (unless otherwise specified as elemental calcium). Dosages expressed in terms of the <span style="text-decoration: underline">calcium chloride salt</span> are based on a solution concentration of 100 mg/mL (10%) containing 1.4 mEq (27 mg) elemental calcium per mL.</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5914c62-3220-46b2-be0c-d96b19443139">Beta-blocker overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Beta-blocker overdose (off-label use): </b>Based on limited data: <b>IV:</b> Initial: Using a 10% solution: 20 <b>mg/kg</b> over 5 to 10 minutes (maximum: 1 to 2 <b>g/dose</b>); may repeat every 10 to 20 minutes for 3 to 4 additional doses <b>or</b> initiate a continuous infusion of 20 to 40 <b>mg/kg/hour</b> titrated to improve hemodynamic response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-15898828','lexi-content-ref-17482022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-15898828','lexi-content-ref-17482022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c249f3aa-2980-4cf2-b10a-11628f338aea">Calcium channel blocker overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker overdose (off-label use): </b>Based on limited data: <b>IV:</b> Initial: Using a 10% solution: 20 <b>mg/kg</b> over 5 to 10 minutes (maximum: 1 to 2 <b>g/dose</b>); may repeat every 10 to 20 minutes for 3 to 4 additional doses <b>or</b> initiate a continuous infusion of 20 to 40 <b>mg/kg/hour</b> titrated to improve hemodynamic response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586772','lexi-content-ref-33081529','lexi-content-ref-15898828','lexi-content-ref-17482022','lexi-content-ref-27749343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586772','lexi-content-ref-33081529','lexi-content-ref-15898828','lexi-content-ref-17482022','lexi-content-ref-27749343'])">Ref</a></span>). <b>Note:</b> Some recommend maintaining serum ionized calcium at a goal of twice normal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17482022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17482022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="218a5213-a03c-48f3-b08c-fef2754f2217">Calcium replacement, during CRRT with citrate-based regional anticoagulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium replacement, during CRRT with citrate-based regional anticoagulation (off-label dose):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intracircuit, posthemodialysis filter (returning to the patient) or IV through a separate central line:</b> Prior to the initiation of CRRT, ensure adequate systemic ionized calcium concentrations (drawn directly from the patient). During CRRT, use a calcium chloride continuous infusion sliding scale to maintain systemic ionized calcium between ~3.6 to 5.2 <b>mg/dL</b> (~0.9 to 1.3 mmol/L); monitor systemic ionized calcium every 6 hours (or more frequently when indicated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19690224','lexi-content-ref-27866200','lexi-content-ref-29151020','lexi-content-ref-17699194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19690224','lexi-content-ref-27866200','lexi-content-ref-29151020','lexi-content-ref-17699194'])">Ref</a></span>). Refer to institutional protocols.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2aced19d-8e31-42bf-bea8-4f1531ddba82">Cardiac arrest or cardiotoxicity in the presence of hypocalcemia or hypermagnesemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac arrest or cardiotoxicity in the presence of hypocalcemia or hypermagnesemia (off-label use): </b>
<b>Note:</b> Routine use in cardiac arrest is not recommended due to the lack of improved survival (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-34847226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-34847226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Intraosseous:</b> 500 to 1,000 mg as a rapid bolus; may repeat as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-34847226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-34847226'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20b6999a-0990-4a13-a395-5b9144f1b648">Hydrofluoric acid exposure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hydrofluoric acid exposure (off-label use):</b>
<b>Note: </b>Consultation with a clinical toxicology or poison control center is recommended prior to the use of calcium chloride for hydrofluoric acid exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic toxicity: </i>
<b>Note: </b>Calcium chloride has been used in the treatment of systemic toxicity secondary to hydrofluoric acid exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3184225','lexi-content-ref-17906993','lexi-content-ref-21171855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3184225','lexi-content-ref-17906993','lexi-content-ref-21171855'])">Ref</a></span>); however, calcium gluconate may be preferred due to the potential for more severe extravasation with calcium chloride.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Exact dose has not been established; clinicians should tailor dose based on patient-specific needs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21171855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21171855'])">Ref</a></span>). Bolus doses of up to 4 g have been required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21171855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21171855'])">Ref</a></span>); repeat as needed based on symptoms of toxicity (eg, cardiac arrhythmias) and serum calcium concentration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hydrofluoric acid burns (severe): </i>
<b>Intra-arterial: </b>10% solution: Add 10 <b>mL</b> of a 10% solution in 40 to 50 mL of D<sub>5</sub>W; infuse over 4 hours into the artery that provides the vascular supply to the affected area. Pain usually resolves by the end of the infusion; repeat if pain recurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3740574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3740574'])">Ref</a></span>); calcium gluconate may be preferred due to the potential for vessel injury and extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Su.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Su.1'])">Ref</a></span>). <b>This intervention should be used only by those accustomed to this technique. Care should be taken to avoid the extravasation.</b> A poison information center or clinical toxicologist should be consulted prior to implementation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="637f3b98-5df7-446f-8c61-563a0b944ec9">Hyperkalemia, severe/emergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia</b>
<b>, severe/emergent (off-label use): Note: </b>Use in patients with hyperkalemia-associated ECG changes <b>or</b> serum potassium &gt;6.5 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31706619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31706619'])">Ref</a></span>). Stabilizes myocardial cell membrane without impacting plasma potassium concentrations; must combine with insulin/dextrose to decrease plasma potassium levels and other therapies to eliminate potassium from body (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529'])">Ref</a></span>). Perform continuous cardiac monitoring and obtain serial ECGs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31706619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31706619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Intraosseous:</b> Initial: 0.5 to 1 g over 2 to 5 minutes; may repeat after 5 minutes if ECG changes persist or recur, then every 30 to 60 minutes as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-Mount.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3efa3fa-5c82-45c1-a52e-39d2f2c63cc0">Hypocalcemia, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia, acute (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with severe symptoms of hypocalcemia (eg, tetany, seizures, carpopedal spasm), ECG abnormalities (eg, QTc prolongation, arrhythmia), or an acute decrease in albumin-corrected serum calcium levels to &lt;7 to 7.5 mg/dL (&lt;1.75 to 1.87 mmol/L) when serious complications may occur if untreated (eg, following neck surgery). In patients <b>without</b> a central line, calcium gluconate is preferred over calcium chloride due to the potential for more severe extravasation with calcium chloride. Correct concurrent hypomagnesemia if present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200','lexi-content-ref-22439169','lexi-content-ref-Goltzman.1','lexi-content-ref-27935815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200','lexi-content-ref-22439169','lexi-content-ref-Goltzman.1','lexi-content-ref-27935815'])">Ref</a></span>). <b>Do not</b> use IV calcium as initial therapy in patients with chronic kidney disease who are asymptomatic or who have stable hypocalcemia with only mild symptoms (eg, paresthesias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goltzman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goltzman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial bolus dose(s):</i>
<b>IV:</b> Add 1 g (10 <b>mL</b> of a 10% solution) to 100 mL of D5W or NS (equivalent to 270 mg <b>elemental calcium</b>). Infuse via a central or large vein over 10 to 20 minutes; may repeat bolus dose after 10 to 60 minutes if symptoms persist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22475676','lexi-content-ref-Goltzman.1','lexi-content-ref-32180591','lexi-content-ref-27935815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22475676','lexi-content-ref-Goltzman.1','lexi-content-ref-32180591','lexi-content-ref-27935815'])">Ref</a></span>). If hypocalcemia is expected to persist (eg, hypoparathyroidism, pancreatitis), follow bolus dose(s) with a continuous IV calcium infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200','lexi-content-ref-22475676','lexi-content-ref-27935815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200','lexi-content-ref-22475676','lexi-content-ref-27935815'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous infusion:</i> IV<b>:</b> Add 4 g (40 <b>mL</b> of a 10% solution) to 960 mL of D5W or NS (equivalent to ~1 g <b>elemental calcium</b> in a final total volume of 1,000 mL). Initiate infusion at 50 to 100 mL/hour (equivalent to ~50 to 100 mg/hour of <b>elemental calcium</b>) via a central or large vein; adjust dose to maintain albumin-corrected serum calcium levels at the low end of normal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200','lexi-content-ref-32022081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200','lexi-content-ref-32022081'])">Ref</a></span>). Initiate oral calcium and vitamin D supplements as soon as possible; once an effective regimen is achieved, taper IV calcium infusion slowly (eg, over 24 to 48 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200'])">Ref</a></span>). <b>Note:</b> Instructions for preparing calcium chloride infusion are adapted from recommendations for calcium gluconate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991881"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: Do not </b>use IV calcium as initial therapy in patients with chronic kidney disease who are asymptomatic or who have stable hypocalcemia with only mild symptoms (eg, paresthesias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goltzman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goltzman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Initiate with lowest dose of the recommended dosage range.</p></div>
<div class="block doha drugH1Div" id="F50989218"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations.</p></div>
<div class="block adr drugH1Div" id="F144476"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (Carlon 1978), hypotension (Carlon 1978), peripheral vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cutaneous calcification (Ehsani 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Medicine-like taste (calcium taste)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction, localized burning</p></div>
<div class="block coi drugH1Div" id="F144490"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Patients with ventricular fibrillation; patients with asystole and electromechanical dissociation; concomitant use of IV calcium chloride with ceftriaxone in neonates (≤28 days of age).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F144473"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation. Extravasation may result in severe necrosis and sloughing. Monitor the IV site closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Acidosis: Use with caution in patients with respiratory acidosis, renal impairment, or respiratory failure; acidifying effect of calcium chloride may potentiate acidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hydrofluoric acid burns: Calcium chloride can be administered intra-arterially for severe hydrofluoric acid exposures. However, the chloride salt should never be injected into tissues (do <b>not</b> inject SUBQ or IM) due to the risk of tissue necrosis (Smith 2019). Consultation with a clinical toxicologist or a poison information center before using calcium chloride to treat hydrofluoric acid toxicity is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperphosphatemia: Use with caution in patients with severe hyperphosphatemia as elevated levels of phosphorus and calcium may result in soft tissue and pulmonary arterial calcium-phosphate precipitation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Use with caution in patients with severe hypokalemia as acute rises in serum calcium levels may result in life-threatening cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypomagnesemia: Hypomagnesemia is a common cause of hypocalcemia; therefore, correction of hypocalcemia may be difficult in patients with concomitant hypomagnesemia. Evaluate serum magnesium and correct hypomagnesemia (if necessary), particularly if initial treatment of hypocalcemia is refractory.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with chronic renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ceftriaxone: Ceftriaxone may complex with calcium causing precipitation. Fatal lung and kidney damage associated with calcium-ceftriaxone precipitates has been observed in premature and term neonates. Due to reports of precipitation reaction in neonates, do not coadminister ceftriaxone with calcium-containing solutions, even via separate infusion lines/sites or at different times in any neonate. Ceftriaxone should not be administered simultaneously with any calcium-containing solution via a Y-site in any patient. However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another for use in patients <b>other than neonates</b> if infusion lines are thoroughly flushed (with a compatible fluid) between infusions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Digoxin: Use with caution in digitalized patients; hypercalcemia may precipitate cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate product selection: Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over or under dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of use: Avoid metabolic acidosis (ie, administer only up to 2 to 3 days then change to another calcium salt).</p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: For IV use only; do not inject SUBQ or IM. Avoid too rapid IV administration (do not exceed 100 mg/minute except in emergency situations); arrythmia, bradycardia, cardiac arrest, hypotension, syncope, and vasodilation may occur.</p></div>
<div class="block dosfc drugH1Div" id="F21879435"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">1 g calcium chloride = elemental calcium 270 mg = calcium 14 mEq = calcium 6.8 mmol</p></div>
<div class="block foc drugH1Div" id="F144484"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (10 mL)</p></div>
<div class="block geq drugH1Div" id="F144469"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323032"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $0.89 - $2.43</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866172"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calciject: 10% (10 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (10 mL)</p></div>
<div class="block adip drugH1Div" id="F53565656"><span class="drugH1">Additional Information</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Elemental Calcium Content of Calcium Salts</b></caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Calcium salt</p></th>
<th align="center">
<p style="text-indent:0em;">Elemental calcium</p>
<p style="text-indent:0em;">(mg/1 g of salt form)</p></th>
<th align="center">
<p style="text-indent:0em;">Calcium</p>
<p style="text-indent:0em;">(mEq/g)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium acetate</p></td>
<td align="center">
<p style="text-indent:0em;">253 mg</p></td>
<td align="center">
<p style="text-indent:0em;">12.7 mEq</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium carbonate</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg</p></td>
<td align="center">
<p style="text-indent:0em;">20 mEq</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium chloride</p></td>
<td align="center">
<p style="text-indent:0em;">270 mg</p></td>
<td align="center">
<p style="text-indent:0em;">14 mEq</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium citrate</p></td>
<td align="center">
<p style="text-indent:0em;">211 mg</p></td>
<td align="center">
<p style="text-indent:0em;">10.5 mEq</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium glubionate</p></td>
<td align="center">
<p style="text-indent:0em;">63.8 mg</p></td>
<td align="center">
<p style="text-indent:0em;">3.2 mEq</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium gluconate</p></td>
<td align="center">
<p style="text-indent:0em;">93 mg</p></td>
<td align="center">
<p style="text-indent:0em;">4.65 mEq</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium lactate</p></td>
<td align="center">
<p style="text-indent:0em;">130 mg</p></td>
<td align="center">
<p style="text-indent:0em;">6.5 mEq</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium phosphate (tribasic)</p></td>
<td align="center">
<p style="text-indent:0em;">390 mg</p></td>
<td align="center">
<p style="text-indent:0em;">19.3 mEq</p></td></tr></tbody></table></div>
<div class="block admp drugH1Div" id="F52612346"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do not use scalp vein or small hand or foot veins for IV administration; central-line administration is the preferred route. Not for endotracheal administration. Do not inject calcium salts IM or administer SUBQ since severe necrosis and sloughing may occur; extravasation of calcium can result in severe necrosis and tissue sloughing. Stop the infusion if the patient complains of pain or discomfort. Warm solution to body temperature prior to administration. Do not infuse calcium chloride in the same IV line as phosphate-containing solutions or with ceftriaxone.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Avoid rapid administration; do not exceed 100 mg/minute except in emergency situations. For patients in cardiac arrest or with calcium channel blocker toxicity, administer as a bolus over 5 to 10 minutes via a central line or intraosseous route (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-20956230'])">Ref</a></span>). For intermittent infusions, administer diluted solutions over &gt;30 to 60 minutes via a central line (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer as a continuous infusion via an infusion pump.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral nutrition solution: Calcium chloride is not routinely used in the preparation of parenteral nutrition. Calcium-phosphate stability and precipitation in parenteral nutrition solution are dependent upon the pH of the solution, temperature, relative concentration of each ion, and salt formulation for Ca and PO<sub>4</sub>. Calcium chloride has a higher propensity to precipitate than calcium gluconate. The pH of the solution is primarily dependent upon the amino acid concentration and composition. The higher percentages of amino acids result in solutions with a lower pH, which decreases the risk for calcium and phosphate precipitation. Individual commercially available amino acid solutions vary significantly with respect to pH lowering potential and consequent calcium phosphate compatibility; consult product-specific labeling and solubility curve data for additional information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26317344','lexi-content-ref-29443921','lexi-content-ref-22245762','lexi-content-ref-31324864']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26317344','lexi-content-ref-29443921','lexi-content-ref-22245762','lexi-content-ref-31324864'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Early/acute calcium extravasation: </i>If acute extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry warm compresses; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Delayed calcium extravasation: </i>If delayed extravasation suspected, closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of cutaneous calcinosis occurs, may initiate sodium thiosulfate antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F144487"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV administration only. Not for IM or SUBQ administration (severe necrosis and sloughing may occur). Avoid rapid administration (do not exceed 100 mg/minute except in emergency situations). For patients in cardiac arrest, administer as a rapid bolus via a central line or intraosseous route (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228','lexi-content-ref-34847226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228','lexi-content-ref-34847226'])">Ref</a></span>). For intermittent IV infusion, infuse diluted solution over 1 hour or no greater than 45 to 90 mg/kg/hour (0.6 to 1.2 mEq/kg/hour); administration via a central or deep vein is preferred; do not use small hand or foot veins for IV administration (severe necrosis and sloughing may occur). Typical rates of administration may vary with indication; refer to institutional protocol. Monitor ECG if calcium is infused faster than 2.5 mEq/minute; <b>stop the infusion if the patient complains of pain or discomfort.</b> Warm solution to body temperature prior to administration. <b>Do not infuse calcium chloride in the same IV line as phosphate-containing solutions.</b></p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Hydrofluoric acid burns (severe) (off-label use/route):</b>
<b>Intra-arterial</b>: Requires radiology to place an arterial catheter in an artery supplying blood to the area of exposure; infuse over 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3740574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3740574'])">Ref</a></span>). <b>This intervention should be used only by those trained in this technique. Care should be taken to avoid the extravasation.</b> A poison information center or clinical toxicologist should be consulted prior to implementation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Early/acute calcium extravasation:</i> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32341081','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32341081','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hyaluronidase: <b>Intradermal or SUBQ:</b> Inject a total of 1 to 1.7 mL (15 units/mL) as 5 separate 0.2 to 0.3 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer intravenously through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Delayed calcium extravasation: </i>Closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of calcinosis cutis occurs, may initiate sodium thiosulfate antidote.</p>
<p style="text-indent:-2em;margin-left:6em;">Sodium thiosulfate: IV: 12.5 g over 30 minutes, administered 3 times per week; may increase gradually to 25 g 3 times per week; monitor for non-anion gap acidosis, hypocalcemia, severe nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F2841703"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not refrigerate solutions; IV infusion solutions in D5W, LR, NS, or other appropriate solutions are stable for 24 hours at room temperature.</p>
<p style="text-indent:-2em;margin-left:2em;">Although calcium chloride is not routinely used in the preparation of parenteral nutrition, it is important to note that phosphate salts may precipitate when mixed with calcium salts. Solubility is improved in amino acid parenteral nutrition solutions. Check with a pharmacist to determine compatibility.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 10 g of calcium chloride be stocked. Suggested amount is stated to be a sufficient quantity to provide antidotal treatment for 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53565804"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute, symptomatic hypocalcemia (FDA approved in pediatric patients [age not specified] and adults); has also been used for calcium channel blocker toxicity, treatment of low cardiac output, treatment of symptomatic hyperkalemia or hypermagnesemia, parenteral nutrition, and post-cardiac arrest resuscitation.</p></div>
<div class="block mst drugH1Div" id="F5360788"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calcium chloride may be confused with calcium gluconate</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calcium chloride may be confused with calcium gluconate.</p>
<p style="text-indent:-2em;margin-left:4em;">Confusion with the different intravenous salt forms of calcium has occurred. There is a threefold difference in the primary cation concentration between <b>calcium chloride</b> (in which 1 g = 14 mEq [270 mg] of elemental Ca++) and <b>calcium gluconate</b> (in which 1 g = 4.65 mEq [93 mg] of elemental Ca++).</p>
<p style="text-indent:-2em;margin-left:4em;">Prescribers should specify which salt form is desired. To prevent medication errors, dosages should be expressed either as mg or grams of the salt form for most indications. Dosages expressed as mEq may be used for nutrition.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298938"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F144478"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone is contraindicated in neonates (28 days of age or younger) who require (or are expected to require) treatment with IV calcium-containing solutions. In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13333807"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to use as an antidote in pregnancy is limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (AHA [Jeejeebhoy 2015]).</p></div>
<div class="block mopp drugH1Div" id="F53565784"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum calcium (ionized calcium preferred if available), albumin, phosphate, magnesium, heart rate, ECG when clinically appropriate.</p></div>
<div class="block rerp drugH1Div" id="F53565657"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Ranges may slightly vary by individual laboratories.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Normal Calcium Values (Lo 2020)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left"></th>
<th align="left">
<p style="text-indent:0em;">Age</p></th>
<th align="left">
<p style="text-indent:0em;">Serum concentration</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left" rowspan="6">
<p style="text-indent:0em;">Calcium, total</p></td>
<td align="left">
<p style="text-indent:0em;">Cord blood</p></td>
<td align="left">
<p style="text-indent:0em;">9 to 11.5 mg/dL (SI: 2.3 to 2.9 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Newborn 3 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">9 to 10.6 mg/dL (SI: 2.3 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">24 to 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">7 to 12 mg/dL (SI: 1.8 to 3 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">4 to 7 days</p></td>
<td align="left">
<p style="text-indent:0em;">9 to 10.9 mg/dL (SI: 2.3 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Child</p></td>
<td align="left">
<p style="text-indent:0em;">8.8 to 10.8 mg/dL (SI: 2.2 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Adolescent to Adult</p></td>
<td align="left">
<p style="text-indent:0em;">8.4 to 10.2 mg/dL (SI: 2.1 to 2.6 mmol/L)</p></td></tr>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;">Calcium, ionized, whole blood</p></td>
<td align="left">
<p style="text-indent:0em;">Cord blood</p></td>
<td align="left">
<p style="text-indent:0em;">5 to 6 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Newborn 3 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">4.3 to 5.1 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">24 to 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">4 to 4.7 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥2 days</p></td>
<td align="left">
<p style="text-indent:0em;">4.8 to 4.92 mg/dL (2.24 to 2.46 mEq/L)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">In low albumin states if ionized calcium in unavailable, the corrected <b>total </b>serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL [SI: 40 g/L]):</p>
<p style="text-indent:-2em;margin-left:4em;">Corrected total calcium (mg/dL) = measured serum calcium (mg/dL) + 0.8 (4 − measured serum albumin [g/dL])</p></div>
<div class="block pha drugH1Div" id="F144472"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Moderates nerve and muscle performance via action potential excitation threshold regulation.</p>
<p style="text-indent:-2em;margin-left:2em;">In hydrofluoric acid (hydrogen fluoride) exposures, calcium chloride provides an exogenous source of calcium which can bind fluoride ions as well as treat and prevent complications secondary to hypocalcemia; intra-arterial administration can reduce the penetration of the fluoride ion into tissues and prevent or reduce tissue destruction and pain (Vance 1986; Wu 2010).</p></div>
<div class="block phk drugH1Div" id="F144489"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Primarily in skeleton (99%).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~40%, primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces (80% as insoluble calcium salts); urine (20%) (IOM 2011).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F3429680"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de calcio</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Calciumchlorid fresenius kabi aus</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Calciclo</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de calcio</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Calcium chloratum</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Calciumchlorid | Calciumchlorid Baxter</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de calcio</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Calcii chloridum</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cloruro calcico Braun</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Calcium cooper | Chlorure de calacium cooper | Chlorure de calcium aguettant</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Calcium chloratum</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Nelcium</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Calcio Cloruro | Calcio cloruro monico</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Calcium chloride kobayashi | Calcium chloride merck hoei | Calcium chloride nipro | Chlocalin | Encal hikari | Encal otsuka</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Huons Calcium Chloride | Jw 3% calcium chloride</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Calcium chloratum | Calcium chloridum | Calciumchlorid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Calcii chloridum | Calcium chloratum</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Calciumklorid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Calcium chloratum</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Calrecia | Kalciumklorid APL</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Calcium chloratum</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Calcium chloratum</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de calcio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-CFR.1">
<a name="CFR.1"></a>Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASPEN.1">
<a name="ASPEN.1"></a>American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. http://www.nutritioncare.org/PNDosing. Updated November 17, 2020. Accessed November 28, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15064673">
<a name="15064673"></a>Ariyan CE, Sosa JA. Assessment and Management of Patients With Abnormal Calcium. <i>Crit Care Med</i>. 2004;32(4)(suppl):146-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/15064673/pubmed" id="15064673" target="_blank">15064673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19687715">
<a name="19687715"></a>Arroyo AM, Kao LW. Calcium Channel Blocker Toxicity. <i>Pediatr Emer Care</i>. 2009;25(8):532-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/19687715/pubmed" id="19687715" target="_blank">19687715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26687150">
<a name="26687150"></a>Averin K, Villa C, Krawczeski CD, et al. Initial observations of the effects of calcium chloride infusions in pediatric patients with low cardiac output. <i>Pediatr Cardiol</i>. 2016;37(3):610-617. doi:10.1007/s00246-015-1322-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/26687150/pubmed" id="26687150" target="_blank">26687150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1532633">
<a name="1532633"></a>Bilezikian JP. Management of Acute Hypercalcemia. <i>N Engl J Med</i>. 1992;326(18):1196-1215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/1532633/pubmed" id="1532633" target="_blank">1532633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26938200">
<a name="26938200"></a>Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future.<i> J Clin Endocrinol Metab</i>. 2016;101(6):2313-2324. doi:10.1210/jc.2015-3910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/26938200/pubmed" id="26938200" target="_blank">26938200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2664428">
<a name="2664428"></a>Binder LS. Acute Arthropod Envenomation: Incidence, Clinical Features, and Management. <i>Med Toxicol Adverse Drug Exp</i>. 1989;4(3):163-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/2664428/pubmed" id="2664428" target="_blank">2664428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19690224">
<a name="19690224"></a>Burry LD, Tung DD, Hallett D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. <i>Ann Pharmacother</i>. 2009;43(9):1419-1425. doi:10.1345/aph.1M182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/19690224/pubmed" id="19690224" target="_blank">19690224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1875846">
<a name="1875846"></a>Brimacombe JR, Scully M, Swainston R. Propranolol overdose--a dramatic response to calcium chloride. <i>Med J Aust</i>. 1991;155(4):267-268. doi:10.5694/j.1326-5377.1991.tb142238.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/1875846/pubmed" id="1875846" target="_blank">1875846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2246705">
<a name="2246705"></a>Broner CW, Stidham GL, Westenkirchner DF, Watson DC. A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children. <i>J Pediatr</i>. 1990;117(6):986-989. doi:10.1016/s0022-3476(05)80151-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/2246705/pubmed" id="2246705" target="_blank">2246705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brubacher.1">
<a name="Brubacher.1"></a>Brubacher JR. Beta-adrenergic antagonists. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanRegent.1">
<a name="AmericanRegent.1"></a>Calcium chloride [prescribing information]. Shirley, NY: American Regent; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanRegent.1">
<a name="AmericanRegent.1"></a>Calcium chloride [prescribing information]. Lake Forest, IL: Hospira, Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Medefil.1">
<a name="Medefil.1"></a>Calcium Chloride (Dihydrate) [prescribing information]. Glendale Heights, IL: Medefil Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-678101">
<a name="678101"></a>Carlon GC, Howland WS, Goldiner PL, Kahn RC, Bertoni G, Turnbull AD. Adverse effects of calcium administration. Report of two cases. <i>Arch Surg</i>. 1978;113(7):882-885. doi:10.1001/archsurg.1978.01370190104021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/678101/pubmed" id="678101" target="_blank">678101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7864486">
<a name="7864486"></a>Chin RL, Garmel GM, Harter PM. Development of Ventricular Fibrillation After Intravenous Calcium Chloride Administration in a Patient With Supraventricular Tachycardia. <i>Ann Emerg Med</i>. 1995;25(3):416-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/7864486/pubmed" id="7864486" target="_blank">7864486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corkins.1">
<a name="Corkins.1"></a>Corkins MR, Balint J, Corkins KG, Bobo E, Plogsted S, Yaworski, JA, eds. <i>A.S.P.E.N. Pediatric Nutrition Support Handbook</i>. 2nd ed. American Society for Enteral and Parenteral Nutrition; 2015:chap. 35.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26473000">
<a name="26473000"></a>de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric advanced life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18)(suppl 2):S526-S542. doi:10.1161/CIR.0000000000000266<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/26473000/pubmed" id="26473000" target="_blank">26473000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Department Health &amp; Human Services, Food Drug Administration. Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition. <i>Federal Register</i>. 2000;65(17):4103-4111.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15898828">
<a name="15898828"></a>DeWitt CR, Walsman JC. Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and Beta-Blocker Toxicity. <i>Toxicol Rev</i>. 2004;23(4):223-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/15898828/pubmed" id="15898828" target="_blank">15898828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17400132">
<a name="17400132"></a>Dickerson RN. Treatment of Hypocalcemia in Critical Illness - Part 1. <i>Nutrition</i>. 2007;23(4):358-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/17400132/pubmed" id="17400132" target="_blank">17400132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17360159">
<a name="17360159"></a>Dickerson RN. Treatment of Hypocalcemia in Critical Illness - Part 2. <i>Nutrition</i>. 2007;23(5):436-437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/17360159/pubmed" id="17360159" target="_blank">17360159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17459309">
<a name="17459309"></a>Ehsani AH, Abedini R, Ghiasi M, Hoseini MS. Calcinosis cutis complicating liver transplantation. <i>Dermatol Online J</i>. 2006;12(7):23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/17459309/pubmed" id="17459309" target="_blank">17459309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22439169">
<a name="22439169"></a>Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. <i>Can Fam Physician</i>. 2012;58(2):158-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/22439169/pubmed" id="22439169" target="_blank">22439169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22475676">
<a name="22475676"></a>French S, Subauste J, Geraci S. Calcium abnormalities in hospitalized patients. <i>Southern Med J</i>. 2012;105(4):231-237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/22475676/pubmed" id="22475676" target="_blank">22475676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goltzman.1">
<a name="Goltzman.1"></a>Goltzman D. Treatment of hypocalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3184225">
<a name="3184225"></a>Greco RJ, Hartford CE, Haith LR Jr, Patton ML. Hydrofluoric acid-induced hypocalcemia. <i>J Trauma</i>. 1988;28(11):1593-1596. doi:10.1097/00005373-198811000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/3184225/pubmed" id="3184225" target="_blank">3184225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs. Preparing for Pediatric Emergencies: Drugs to Consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2860911">
<a name="2860911"></a>Henry M, Kay MM, Viccellio P. Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride. <i>Am J Emerg Med</i>. 1985;3(4):334-336. doi:10.1016/0735-6757(85)90060-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/2860911/pubmed" id="2860911" target="_blank">2860911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7909677">
<a name="7909677"></a>Howarth DM, Dawson AH, Smith AJ, et al. Calcium Channel Blocking Drug Overdose: An Australian Series. <i>Hum Exp Toxicol</i>. 1994;13(3):161-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/7909677/pubmed" id="7909677" target="_blank">7909677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15013473">
<a name="15013473"></a>Hsu SC, Levine MA. Perinatal calcium metabolism: physiology and pathophysiology. <i>Semin Neonatol</i>. 2004;9(1):23-36. doi:10.1016/j.siny.2003.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/15013473/pubmed" id="15013473" target="_blank">15013473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29443921">
<a name="29443921"></a>Huston RK, Christensen JM, Alshahrani SM, et al. Calcium chloride and calcium gluconate in neonatal parenteral nutrition solutions without cysteine: compatibility studies using laser light obscuration methodology. <i>Nutrients</i>. 2018;10(2):208. doi:10.3390/nu10020208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/29443921/pubmed" id="29443921" target="_blank">29443921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26317344">
<a name="26317344"></a>Huston RK, Christensen JM, Alshahrani SM, et al. Calcium chloride in neonatal parenteral nutrition solutions with and without added cysteine: compatibility studies using laser and micro-flow imaging methodology. <i>PLoS One</i>. 2015;10(8):e0136894. doi:10.1371/journal.pone.0136894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/26317344/pubmed" id="26317344" target="_blank">26317344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12101159">
<a name="12101159"></a>Isbister GK. Continuous Calcium Chloride Infusion for Massive Nifedipine Overdose. <i>Emerg Med J</i>. 2002;19(4):355-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/12101159/pubmed" id="12101159" target="_blank">12101159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jang.1">
<a name="Jang.1"></a>Jang DH. Calcium channel blockers. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi:10.1161/CIR.0000000000000300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7137684">
<a name="7137684"></a>Jones JL. Metoprolol overdose. <i>Ann Emerg Med</i>. 1982;11(2):114-115. doi:10.1016/s0196-0644(82)80324-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/7137684/pubmed" id="7137684" target="_blank">7137684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17482022">
<a name="17482022"></a>Kerns W 2nd. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. <i>Emerg Med Clin North Am</i>. 2007;25(2):309-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/17482022/pubmed" id="17482022" target="_blank">17482022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27866200">
<a name="27866200"></a>Kirwan CJ, Hutchison R, Ghabina S, et al. Implementation of a simplified regional citrate anticoagulation protocol for post-dilution continuous hemofiltration using a bicarbonate buffered, calcium containing replacement solution. <i>Blood Purif</i>. 2016;42(4):349-355. doi:10.1159/000452755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/27866200/pubmed" id="27866200" target="_blank">27866200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32180591">
<a name="32180591"></a>Kiser TH, Barber GR, Robinson A. Managing the intravenous calcium shortage: evaluation of calcium chloride stability in 0.9% sodium chloride and dextrose 5% water polyvinyl chloride bags. <i>Hosp Pharm</i>. 2012;47(1):27-30. doi:10.1310/hpj4701-27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/32180591/pubmed" id="32180591" target="_blank">32180591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586772">
<a name="30586772"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2019;140(8):e382-e482. doi:10.1161/CIR.0000000000000628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/30586772/pubmed" id="30586772" target="_blank">30586772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11296202">
<a name="11296202"></a>Lam YM, Tse HF, Lau CP. Delayed Asystolic Cardiac Arrest After Diltiazem Overdose: Resuscitation With High Dose Intravenous Calcium. <i>Chest</i>. 2001;119(4):1280-1282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/11296202/pubmed" id="11296202" target="_blank">11296202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lo.1">
<a name="Lo.1"></a>Lo SF. Reference intervals for laboratory tests and procedures. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 748.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8107735">
<a name="8107735"></a>Luscher TF, Noll G, Sturmer T. Calcium Gluconate in Severe Verapamil Intoxication. <i>N Engl J Med</i>. 1994;330(10):718-720.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/8107735/pubmed" id="8107735" target="_blank">8107735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2360741">
<a name="2360741"></a>Martin TJ, Kang Y, Robertson KM, et al. Ionization and Hemodynamic Effects of Calcium Chloride and Calcium Gluconate in the Absence of Hepatic Function. <i>Anesthesiology</i>. 1990;73(1):62-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/2360741/pubmed" id="2360741" target="_blank">2360741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2182050">
<a name="2182050"></a>McIvor ME. Acute Fluoride Toxicity. Pathophysiology and Management. <i>Drug Saf</i>. 1990;5(2):79-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/2182050/pubmed" id="2182050" target="_blank">2182050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22245762">
<a name="22245762"></a>Migaki EA, Melhart BJ, Dewar CJ, Huston RK. Calcium chloride and sodium phosphate in neonatal parenteral nutrition containing TrophAmine: precipitation studies and aluminum content. <i>JPEN J Parenter Enteral Nutr</i>. 2012;36(4):470-475. doi:10.1177/0148607111420154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/22245762/pubmed" id="22245762" target="_blank">22245762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7836618">
<a name="7836618"></a>Mimouni F, Tsang RC. Neonatal hypocalcemia: to treat or not to treat? (A review). <i>J Am Coll Nutr</i>. 1994;13(5):408-415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/7836618/pubmed" id="7836618" target="_blank">7836618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568296">
<a name="15568296"></a>Mirtallo J, Canada T, Johnson D, et al. Safe Practices for Parenteral Nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/15568296/pubmed" id="15568296" target="_blank">15568296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al. Adult Toxicology in Critical Care: Part II: Specific Poisonings. <i>Chest</i>. 2003;123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34523025">
<a name="34523025"></a>Murray LE, Burchett H, Chowdhury SM, et al. Calcium chloride infusions are not associated with improved outcomes in neonates undergoing cardiac operations. <i>Pediatr Cardiol</i>. 2022;43(2):366-372. doi:10.1007/s00246-021-02730-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/34523025/pubmed" id="34523025" target="_blank">34523025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult basic and advanced life support writing group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1793522">
<a name="1793522"></a>Pearigen PD, Benowitz NL. Poisoning Due to Calcium Antagonists. Experience With Verapamil, Diltiazem, and Nifedipine. <i>Drug Saf</i>. 1991;6(6):408-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/1793522/pubmed" id="1793522" target="_blank">1793522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-709264">
<a name="709264"></a>Perkins CM. Serious verapamil poisoning: treatment with intravenous calcium gluconate. <i>Br Med J</i>. 1978;2(6145):1127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/709264/pubmed" id="709264" target="_blank">709264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624322">
<a name="9624322"></a>Pertoldi F, D'Orlando L, Mercante WP. Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride. <i>Ann Emerg Med</i>. 1998;31(6):777-781.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/9624322/pubmed" id="9624322" target="_blank">9624322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8427431">
<a name="8427431"></a>Ramoska EA, Spiller HA, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. <i>Ann Emerg Med</i>. 1993;22(2):196-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/8427431/pubmed" id="8427431" target="_blank">8427431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534324">
<a name="12534324"></a>Salhanick SD, Shannon MW. Management of Calcium Channel Antagonist Overdose. <i>Drug Saf</i>. 2003;26(2):65-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/12534324/pubmed" id="12534324" target="_blank">12534324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29151020">
<a name="29151020"></a>Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? <i>Crit Care</i>. 2017;21(1):281. doi:10.1186/s13054-017-1880-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/29151020/pubmed" id="29151020" target="_blank">29151020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16990629">
<a name="16990629"></a>Shepherd G. Treatment of Poisoning Caused by β-adrenergic and Calcium-Channel Blockers. <i>Am J Health-Syst Pharm</i>. 2006;63(19):1828-1835.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/16990629/pubmed" id="16990629" target="_blank">16990629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Slattery.1">
<a name="Slattery.1"></a>Slattery A, King WD, Nichols M, et al. Hypercalcemia Following Damp-Rid™ Ingestion. <i>Clin Toxicol</i>. 1995;33(5):487.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.1">
<a name="Smith.1"></a>Smith SW, Howland MA. Calcium. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32341081">
<a name="32341081"></a>Smolders EJ, Benoist GE, Smit CCH, Ter Horst P. An update on extravasation: basic knowledge for clinical pharmacists. <i>Eur J Hosp Pharm.</i> 2020;28(3):165–167. doi:10.1136/ejhpharm-2019-002152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/32341081/pubmed" id="32341081" target="_blank">32341081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27749343">
<a name="27749343"></a>St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium channel blocker poisoning in adults. <i>Crit Care Med.</i> 2017;45(3):e306-e315. doi:10.1097/CCM.0000000000002087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/27749343/pubmed" id="27749343" target="_blank">27749343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Su.1">
<a name="Su.1"></a>Su MK. Hyrdofluoric acid and fluorides. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17699194">
<a name="17699194"></a>Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. <i>Clin J Am Soc Nephrol</i>. 2006;1(1):79-87. doi:10.2215/CJN.00040505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/17699194/pubmed" id="17699194" target="_blank">17699194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081526">
<a name="33081526"></a>Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/33081526/pubmed" id="33081526" target="_blank">33081526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022081">
<a name="32022081"></a>Turner J, Gittoes N, Selby P; Society for Endocrinology Clinical Committee. Society for Endocrinology emergency endocrine guidance: emergency management of acute hypocalcaemia in adult patients. <i>Endocr Connect</i>. 2019;8(6):X1. doi:10.1530/EC-16-0056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/32022081/pubmed" id="32022081" target="_blank">32022081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27935815">
<a name="27935815"></a>Turner J, Gittoes N, Selby P; Society for Endocrinology Clinical Committee. Society for Endocrinology endocrine emergency guidance: emergency management of acute hypocalcaemia in adult patients. <i>Endocr Connect</i>. 2016;5(5):G7-G8. doi:10.1530/EC-16-0056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/27935815/pubmed" id="27935815" target="_blank">27935815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34847226">
<a name="34847226"></a>Vallentin MF, Granfeldt A, Meilandt C, et al. Effect of intravenous or intraosseous calcium vs saline on return of spontaneous circulation in adults with out-of-hospital cardiac arrest: a randomized clinical trial. <i>JAMA</i>. 2021;326(22):2268-2276. doi:10.1001/jama.2021.20929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/34847226/pubmed" id="34847226" target="_blank">34847226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3740574">
<a name="3740574"></a>Vance MV, Curry SC, Kunkel DB, Ryan PJ, Ruggeri SB. Digital hydrofluoric acid burns: treatment with intraarterial calcium infusion. <i>Ann Emerg Med</i>. 1986;15(8):890-896. doi:10.1016/s0196-0644(86)80670-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/3740574/pubmed" id="3740574" target="_blank">3740574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S829-S861. doi:10.1161/CIRCULATIONAHA.110.971069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17906993">
<a name="17906993"></a>Vohra R, Velez LI, Rivera W, Benitez FL, Delaney KA. Recurrent life-threatening ventricular dysrhythmias associated with acute hydrofluoric acid ingestion: observations in one case and implications for mechanism of toxicity. <i>Clin Toxicol (Phila)</i>. 2008;46(1):79-84. doi:10.1080/15563650701639097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/17906993/pubmed" id="17906993" target="_blank">17906993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31320908">
<a name="31320908"></a>Vuralli D. Clinical approach to hypocalcemia in newborn period and infancy: who should be treated? <i>Int J Pediatr</i>. 2019;2019:4318075. doi:10.1155/2019/4318075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/31320908/pubmed" id="31320908" target="_blank">31320908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31324864">
<a name="31324864"></a>Watrobska-Swietlikowska D. Compatibility of maximum inorganic and organic calcium and phosphate content in neonatal parenteral solutions. <i>Sci Rep</i>. 2019;9(1):10525. doi:10.1038/s41598-019-46987-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/31324864/pubmed" id="31324864" target="_blank">31324864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6105319">
<a name="6105319"></a>Worthley LI and Phillips PJ. Intravenous calcium salts. <i>Lancet.</i> 1980;2(8186):149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/6105319/pubmed" id="6105319" target="_blank">6105319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21171855">
<a name="21171855"></a>Wu ML, Deng JF, Fan JS. Survival after hypocalcemia, hypomagnesemia, hypokalemia and cardiac arrest following mild hydrofluoric acid burn. <i>Clin Toxicol (Phila)</i>. 2010;48(9):953-955. doi:10.3109/15563650.2010.533676<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/21171855/pubmed" id="21171855" target="_blank">21171855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1737459">
<a name="1737459"></a>Zaloga GP. Hypocalcemia in critically ill patients. <i>Crit Care Med</i>. 1992;20(2):251-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-chloride-pediatric-drug-information/abstract-text/1737459/pubmed" id="1737459" target="_blank">1737459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1">
<a name="Zenk.1"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12651 Version 262.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
